Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186174 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2HSD17B10RECQLFKBP1A | |
| SCHEMBL154453 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2HSD17B10RECQLFKBP1A | |
| Ammonia Solution, Strong SCHEMBL28111366 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2HSD17B10RECQLFKBP1A | |
| SCHEMBL18555204 | 0.91 | HSD17B10 (0.51) | SMN1; SMN2USP2HSD17B10RECQLKLK7 | |
| SCHEMBL31148667 | 0.91 | HSD17B10 (0.51) | SMN1; SMN2USP2HSD17B10RECQLKLK7 | |
| SCHEMBL18555206 | 0.91 | HSD17B10 (0.51) | SMN1; SMN2USP2HSD17B10RECQLKLK7 | |
| SCHEMBL13804186 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2HSD17B10RECQLCA12 | |
| SCHEMBL15116754 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2HSD17B10RECQLCA12 | |
| SCHEMBL3511572 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2HSD17B10RECQLCA12 | |
| SCHEMBL16359137 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2HSD17B10RECQLCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215886-B | Compounds and compositions as endosomal Toll-like receptor inhibitors | 诺华股份有限公司 | 2024-10-11 | — | — | CN | claimed |
| EP-4059934-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | Novartis AG (CH) | 2022-09-21 | — | — | EP | claimed |
| CN-111533708-B | Preparation method of chiral N-tert-butoxycarbonylmorpholine-3-carboxylic acid | 上海馨远医药科技有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-111533708-A | Preparation method of chiral N-tert-butoxycarbonylmorpholine-3-carboxylic acid | 上海馨远医药科技有限公司 | 2020-08-14 | — | — | CN | claimed |
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122036596-A | N- (2 ',6' -xylyl) -2-piperidine carboxamide derivative and application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | NXERA PHARMA UK LIMITED (GB) | 2025-12-09 | — | — | US | disclosed |
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| EP-1735311-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005111037-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20040235839-A1 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | SMN1; SMN2 3534/4885USP2 4516/4885HSD17B10 586/4885 |
| US-20040235839-A1 | Beta-carbolines useful for treating inflammatory disease | NFKBIA, IRAK2, IRAK1 | SMN1; SMN2 3369/4885USP2 832/4885HSD17B10 3910/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | SMN1; SMN2 1555/4885USP2 4448/4885HSD17B10 1075/4885 |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | PTGER4, PTGER1, PTGER2 | SMN1; SMN2 4073/4885USP2 2890/4885HSD17B10 2189/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | SMN1; SMN2 3226/4885USP2 4447/4885HSD17B10 1259/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | SMN1; SMN2 3286/4885USP2 499/4885HSD17B10 1968/4885 |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP3, DPP7 | SMN1; SMN2 895/4885USP2 1293/4885HSD17B10 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.